Cam Gallagher - Apr 5, 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Director
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Cam S. Gallagher
Stock symbol
ZNTL
Transactions as of
Apr 5, 2022
Transactions value $
-$504,769
Form type
4
Date filed
4/5/2022, 06:52 PM
Previous filing
Mar 16, 2022
Next filing
May 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$217K -4.37K -1.19% $49.72 361K Apr 5, 2022 Direct F1, F2
transaction ZNTL Common Stock Sale -$169K -3.34K -0.92% $50.68 358K Apr 5, 2022 Direct F1, F3
transaction ZNTL Common Stock Sale -$113K -2.2K -0.61% $51.59 356K Apr 5, 2022 Direct F1, F4
transaction ZNTL Common Stock Sale -$5.27K -100 -0.03% $52.70 356K Apr 5, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.20 to $50.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.20 to $51.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.21 to $52.07. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.